PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 24483111-12 2013 Compared with the model group, ALT and AST levels were significantly lower in the RM group and the Bifendate group (P < 0.01); TBil significantly decreased in the RM group (P < 0.01). bifendate 99-108 glutamic pyruvic transaminase, soluble Mus musculus 31-34 25415237-6 2015 Our results show that bifendate, AAP, ASP, and AMP significantly decreased the activities of MDA, AST, and ALT, and enhanced the activity of SOD in CCl4-treated mice. bifendate 22-31 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 98-101 25415237-6 2015 Our results show that bifendate, AAP, ASP, and AMP significantly decreased the activities of MDA, AST, and ALT, and enhanced the activity of SOD in CCl4-treated mice. bifendate 22-31 glutamic pyruvic transaminase, soluble Mus musculus 107-110 25415237-6 2015 Our results show that bifendate, AAP, ASP, and AMP significantly decreased the activities of MDA, AST, and ALT, and enhanced the activity of SOD in CCl4-treated mice. bifendate 22-31 chemokine (C-C motif) ligand 4 Mus musculus 148-152 25415237-7 2015 Bifendate, AAP, ASP, and AMP consistently ameliorated the liver injuries induced with CCl4. bifendate 0-9 chemokine (C-C motif) ligand 4 Mus musculus 86-90 24483111-12 2013 Compared with the model group, ALT and AST levels were significantly lower in the RM group and the Bifendate group (P < 0.01); TBil significantly decreased in the RM group (P < 0.01). bifendate 99-108 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 39-42 24483111-23 2013 The effect of decreasing expressions of Fas and FasL was better in the RM group than in the HAS group, the YD group, and the Bifendate group (P < 0.05). bifendate 125-134 Fas ligand (TNF superfamily, member 6) Mus musculus 48-52 22405646-0 2012 Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors. bifendate 45-54 ATP binding cassette subfamily B member 1 Homo sapiens 126-140 23220523-0 2013 Spectroscopic study on the interaction of catalase with bifendate and analogs. bifendate 56-65 catalase Homo sapiens 42-50 23220523-1 2013 The interactions of bifendate (DDB) or analogs (Bicyclol, I, II and III) with catalase are analyzed by spectrophotometric methods. bifendate 20-29 catalase Homo sapiens 78-86 22405646-2 2012 To find new P-gp inhibitors, a series of bifendate (DDB) derivatives bearing dibenzo[c,e]azepine scaffold were synthesized and evaluated. bifendate 41-50 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 22429509-0 2012 Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors. bifendate 39-48 ATP binding cassette subfamily B member 1 Homo sapiens 94-108 22429509-2 2012 To find novel effective P-gp inhibitors, a series of bifendate-chalcone hybrids were synthesized and evaluated. bifendate 53-62 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 19343062-1 2009 AIM: To evaluate the potential drug-drug interactions between bifendate and cyclosporine, a substrate of CYP3A4, in relation to different CYP3A4*18B genotype groups. bifendate 62-71 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-111 19343062-1 2009 AIM: To evaluate the potential drug-drug interactions between bifendate and cyclosporine, a substrate of CYP3A4, in relation to different CYP3A4*18B genotype groups. bifendate 62-71 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 138-144 19343062-8 2009 CONCLUSION: These results suggest that bifendate decreases the plasma concentration of cyclosporine in a CYP3A4 genotype-dependent manner. bifendate 39-48 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-111 16723084-6 2006 When given at daily doses of 0.25 and 1 g/kg for 4 d, bifendate increased serum TG levels (56%-79%), with concomitant elevations in apolipoprotein A-I and apolipoprotein B levels at 24 h after the last dosing. bifendate 54-63 apolipoprotein A-I Mus musculus 132-150 16723084-6 2006 When given at daily doses of 0.25 and 1 g/kg for 4 d, bifendate increased serum TG levels (56%-79%), with concomitant elevations in apolipoprotein A-I and apolipoprotein B levels at 24 h after the last dosing. bifendate 54-63 apolipoprotein B Mus musculus 155-171 30867448-10 2019 Moreover, bifendate regulate the dysfunction module through ncRNA (SNORD43 and RNU11). bifendate 10-19 RNANC Homo sapiens 60-65 15742813-8 2005 Compound 3 showed much higher inhibitory effects than bifendate for decreasing AST and ALT activity. bifendate 54-63 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 79-82 15742813-8 2005 Compound 3 showed much higher inhibitory effects than bifendate for decreasing AST and ALT activity. bifendate 54-63 glutamic pyruvic transaminase, soluble Mus musculus 87-90 33542935-12 2020 In the wild-type tyrosinase, the peptide oxygen atom of M374 is responsible for hydrogen bonding with H367. bifendate 102-106 tyrosinase Homo sapiens 17-27 30867448-10 2019 Moreover, bifendate regulate the dysfunction module through ncRNA (SNORD43 and RNU11). bifendate 10-19 small nucleolar RNA, C/D box 43 Homo sapiens 67-74 30867448-10 2019 Moreover, bifendate regulate the dysfunction module through ncRNA (SNORD43 and RNU11). bifendate 10-19 RNA, U1 small nuclear 1 Homo sapiens 79-84 30867448-12 2019 On the other hand, proteome analysis showed that bifendate mainly regulated Rac2, Fermt3 and Plg, while muaddil sapra mainly regulated Sqle and Stat1. bifendate 49-58 Rac family small GTPase 2 Homo sapiens 76-80 30867448-12 2019 On the other hand, proteome analysis showed that bifendate mainly regulated Rac2, Fermt3 and Plg, while muaddil sapra mainly regulated Sqle and Stat1. bifendate 49-58 FERM domain containing kindlin 3 Homo sapiens 82-88 30867448-12 2019 On the other hand, proteome analysis showed that bifendate mainly regulated Rac2, Fermt3 and Plg, while muaddil sapra mainly regulated Sqle and Stat1. bifendate 49-58 plasminogen Homo sapiens 93-96 29335204-1 2018 As a continuation of previous research, fifteen bifendate derivatives bearing 6,7-dihydro-dibenzo [c,e]azepine scaffold were synthesized and evaluated as P-gp-medicated multidrug resistance (MDR) reversal agents. bifendate 48-57 phosphoglycolate phosphatase Homo sapiens 154-158 30542532-2 2018 We recently reported a bifendate derivative bearing a dibenzo[c,e]azepine scaffold (4i) as a P-gp and BCRP-medicated MDR reversal agent. bifendate 23-32 phosphoglycolate phosphatase Homo sapiens 93-97 30542532-2 2018 We recently reported a bifendate derivative bearing a dibenzo[c,e]azepine scaffold (4i) as a P-gp and BCRP-medicated MDR reversal agent. bifendate 23-32 BCR pseudogene 1 Homo sapiens 102-106 29335204-2 2018 Biological evaluation indicated that compounds 6k and 9c more potently reversed P-gp-mediated MDR than bifendate and verapamil (VRP) by blocking P-gp mediated drug efflux function and not by decreasing P-gp expression in K562/A02 MDR cells. bifendate 103-112 phosphoglycolate phosphatase Homo sapiens 145-149 29335204-2 2018 Biological evaluation indicated that compounds 6k and 9c more potently reversed P-gp-mediated MDR than bifendate and verapamil (VRP) by blocking P-gp mediated drug efflux function and not by decreasing P-gp expression in K562/A02 MDR cells. bifendate 103-112 phosphoglycolate phosphatase Homo sapiens 145-149 29268129-0 2018 Development of tacrine-bifendate conjugates with improved cholinesterase inhibitory and pro-cognitive efficacy and reduced hepatotoxicity. bifendate 23-32 butyrylcholinesterase Homo sapiens 58-72